Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- CMIC Reports Increases in Sales and Profits Driven by CRO Business
November 8, 2011
- Nichi-Iko to Change Company Structure to Strengthen Sales of Generic Drugs
November 8, 2011
- Kaken to Enhance Detailing Activities for GPs Aiming at Sales Expansion for Lipidil, Generics
November 8, 2011
- Towa Pharmaceutical’s New Business Plan is “Groundwork for Future Progress”
November 8, 2011
- Suzuken President Ota Says Wholesale Business Recovery Crucial
November 8, 2011
- Towa Apr-Sep Earnings Limited on Break in Impact of Premium Revision
November 8, 2011
- Intellim Ties Up with SMO Iberica, Aiming to Enter US Market in 2012
November 8, 2011
- Pfizer Japan Applies for Additional Indication for Sutent for pNET Designated as Orphan Disease
November 8, 2011
- Prices Should Remain Stable in 2nd-Half: Pres. Ishiguro of Alfresa HD
November 8, 2011
- Kobayashi Pharm. to Create 3 Subsidiaries in Southeast Asia
November 8, 2011
- Kyorin HD: Both Sales, Profits Remain Virtually Unchanged
November 8, 2011
- Eli Lilly, Amylin to Terminate Collaboration in Field of Diabetes
November 8, 2011
- Takeda Establishes New Positions in R&D, Global Sales
November 7, 2011
- Takeda Reinstates Request for Probe into Transfer Pricing Taxation
November 7, 2011
- Takeda: Sales, Profits Down due to Strong Yen, Double-digit Decreases in Sales of Actos in Apr-Sep
November 7, 2011
- Suzuken Reports Largest Interim Operating Loss From Drug Wholesale Business
November 7, 2011
- Operating Profits Down 70% in Wholesale Business: Alfresa HD
November 7, 2011
- 8 of 10 Leading Drug Makers Report Declines in 1st-Half Sales
November 7, 2011
- Takeda President Hasegawa Plans to Complete Integration with Nycomed in 3 Years
November 7, 2011
- Ono: Glactiv, Emend Drive Growth in 1st-Half Sales
November 7, 2011
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…